Form 4: Ionis EVP Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Ionis Pharmaceuticals EVP of Research, Eric Swayze, sold 6,849 shares of common stock for a weighted average price of $69.02 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Eric Swayze, Executive Vice President of Research at Ionis Pharmaceuticals Inc. (IONS), reported a sale of common stock.
- The transaction involved the disposition of 6,849 shares of common stock.
- The shares were sold at a weighted average price of $69.02 per share, with individual transactions ranging from $69.02 to $69.03.
- The sale was executed on October 6, 2025, pursuant to a Rule 10b5-1 Trading Plan adopted by Mr. Swayze on August 14, 2024.
- Following the reported transaction, Mr. Swayze directly beneficially owns 30,453 shares of common stock.
- Additionally, 184 shares are indirectly beneficially owned by his son.
Sentiment
Score: 5
Explanation: The transaction is a routine, pre-planned insider sale executed under a Rule 10b5-1 trading plan, which is generally considered neutral as it does not typically signal a change in management's outlook on the company's prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's portfolio management.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The sale was conducted pursuant to a Rule 10b5-1 Trading Plan, which allows insiders to pre-arrange sales of company stock to avoid accusations of trading on material non-public information. | 08/14/2024 | Enhances transparency and compliance with insider trading regulations, demonstrating a structured approach to executive stock sales. |
Related Party Transactions
- Eric Swayze reported indirect beneficial ownership of 184 shares of common stock held by his son.
Stakeholder Impact
- Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal direct impact on shareholder sentiment or company valuation, as it is a pre-scheduled event rather than a reaction to new information.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date Rule 10b5-1 Trading Plan was adopted by Eric Swayze. |
| 10/06/2025 | Date of the reported transaction (sale of common stock). |
| 10/08/2025 | Date the Form 4 was signed by Patrick R. O'Neil, attorney-in-fact for Eric Swayze. |
Recommendation
holdThe filing reports a routine, pre-scheduled insider stock sale by an executive, which does not provide new material information to alter the investment thesis for Ionis Pharmaceuticals. The transaction was executed under a Rule 10b5-1 trading plan, indicating it was pre-planned and not based on immediate, non-public information. Therefore, a 'hold' recommendation is appropriate as this event does not warrant a change in investment strategy.
Keywords
Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Sale, Eric Swayze, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.